C50
Conditions
Interventions
Group 1: Patients with metastatic breast cancer undergoing radiotherapy to at least one metastatic site.
The interventional part is solely based on three additional phlebotomies. The oncological trea
Sponsors
Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Metastatic breast cancer patient undergoing radiotherapy (RT) of macroscopic tumour to at least one metastatic site - > 18 years - Female - Ability to report patient-reported outcomes in case of palliative radiotherapy - Patient gave informed consent
Exclusion criteria
Exclusion criteria: - Patients receiving only RT of a tumour bed/resection cavity with no macroscopic lesion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characterisation of circulating tumor cells and peripheral blood lymphocytes in patients with oligo- and polymetastatic disease. Peripheral blood will be examined at the first and last fraction of radiotherapy as well as the first follow-up at 6 to 8 after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Local control and symptomatic response of treated metastases as well as time to further distant metastasis in dependence of radiobiological factors. | — |
Countries
Germany
Contacts
Public ContactKatharina Hintelmann
Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf
Outcome results
None listed